Our study of risk factors for *T. gondii* infection was a case-control design to evaluate recent infection, not a cross-sectional study of *T. gondii* infection prevalence in a population. In our study, case-patients with recent infection were similar in age to *T. gondii*-negative control-patients, although among women the mean age of case-patients (33 years) differed slightly from that of control-patients (29 years) (*p* = 0.03, *t*-test). In addition, multivariate analysis comparing the case-patients with control-patients showed that age was not a significant factor. However, when we kept age in the multivariate model for women (*p* = 0.87 for age in the model), the odds ratio for having had children changed slightly. The crude ratio for having had children was 14.01 (95% CI 3.68–60.73) to 14.01 (95% CI 2.88–68.08). Therefore, we do think that, in this study population, having had children is a risk factor for *T. gondii* infection among women.

Dr Gomez-Marin also states that we did not evaluate drinking water–related factors. However, in our methods section (1), we indicated that our questionnaire asked about a comprehensive set of risk factors related to drinking water. Specifically, the questionnaire asked about the types of water (city, private well, and others, including bottled water); chlorination; filtering of water; and ingestion of water from streams, lakes, rivers, ponds, or other sources. Although we evaluated numerous water-related factors, we did not find them to be significant in this study, which applies to 1 area of Brazil. In other areas of Brazil, however, studies in which 1 of our authors (J.L.J.) has been involved have found water to be a risk factor or a source of infection (2,3).

Again, we thank Dr Gomez-Marin for his letter. We sincerely appreciate his interest and work with toxoplasmosis.

Jeffrey L. Jones,* Cristina Muccioli,† Rubens Belfort Jr,‡ Gary N. Holland,¶ Jacquein M. Roberts,* and Claudio Silveira§

*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Federal University of São Paulo, São Paulo, Brazil; ‡University of California, Los Angeles, California, USA; and §Clinica Silveira, Erechim, Rio Grande do Sul, Brazil

References

1. Jones JL, Muccioli C, Belfort R, Holland GN, Roberts JM, Silveira C. Recently acquired *Toxoplasma gondii* infection, Brazil. Emerg Infect Dis. 2006;12:582–7.
2. Bahia-Oliveira LM, Jones JL, Azvedo-Silva J, Alves CF, Orefice F, Addiss DG. High endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis. 2003;9:55–62.
3. de Moura L, Bahia Oliveira L, Wada MY, Jones JL, Tuboi SH, Carmo EH, et al. Waterborne toxoplasmosis, Brazil, from field to gene. Emerg Infect Dis. 2006;12:326–9.

Address for correspondence: Jeffrey L. Jones, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop F22, Atlanta, GA 30341-3724, USA; email: jlj1@cdc.gov

---

CTX-M Extended-spectrum β-Lactamases, Washington State

To the Editor: The CTX-M–type β-lactamases are non-TEM and non-SHV plasmid-mediated, class A, extended-spectrum β-lactamases (ESBLs). The CTX-M–type β-lactamases have recently emerged as the most common type of ESBLs, with a global distribution (1). In contrast, the CTX-M–type ESBLs are rarely reported in the United States and have not been identified in pathogens isolated from infected patients with gastroenteritis.

We screened 637 *Salmonella* and 126 *Shigella* isolates, collected in the state of Washington during 2003–2004, for CTX-M–type β-lactamases. Of these, 60 *Salmonella* isolates that exhibited an ESBL phenotype were further characterized by PCR for TEM, SHV, CTM-X, and CMY. All were positive for the CMY-2 or TEM-1 β-lactam genes. One *Shigella sonnei* isolate (WA7593), cultured from a fecal specimen in August 2004, tested positive with an ESBL confirmatory disk diffusion panel (ceftazidime 24 mm, cefotaxime/clavulanate 32 mm, cefotaxime 14 mm, and ceftaxime/clavulanate 34 mm; [2]). The patient had recently traveled to Pakistan and likely became ill there and returned to the United States while still sick. The transfer of extended-spectrum cephalosporin resistance was tested by conjugation to *Escherichia coli* J53 *azi* β (3). The MIC for *S. sonnei* WA7593 and its transconjugant, WA7593TC1, were tested by using the E-test (AB Biodisk, Solna, Sweden). Both strains were resistant to cefotaxime and susceptible to cefuzidime and showed almost the same antimicrobial susceptibility patterns as β-lactam antimicrobial drugs (Table).

The type of ESBL produced by these strains was determined by using PCR specific for TEM and CTX-M (4,5). Both strains were PCR positive for TEM and CTX-M. The TEM type PCR products were then sequenced and identified as TEM-1; no variation was found on the promoter region of *bla* TEM-1. The entire sequence of *bla* CTX-M from WA7593 was then sequenced (1), and the product showed 100% homology with *bla* CTX-M-1 (GenBank accession no. AY960984). The mobile element associated with the transfer of *bla* CTX-M-1 was investigated by sequencing the flanking regions.
PCRs were performed with primers from the internal regions of \textit{bla}_{\text{CTX-M}} gene and primers for insertion sequences \textit{ISEcp1} and IS903 (4,5). Positive PCR products were obtained with primers \textit{ISEcp1}F and CTX2 (943 bp); no amplified product was produced with primers CTX1 and IS903R. Sequencing of a 943-bp amplicon showed that \textit{bla}_{\text{CTX-M15}} was flanked upstream by an \textit{ISEcp1}-like element.

The presence of an integron in \textit{S. sonnei} WA7593 and WA7593TC1 was investigated by using integron-specific primers hep35 and hep36 (2). Only \textit{S. sonnei} WA7593 produced a PCR product. This finding suggests that the transmission of \textit{bla}_{\text{CTX-M15}} is not by integron-mediated transfer. A further 162 \textit{Shigella} spp. and 260 \textit{Salmonella} spp. isolated from 2003 through 2005 were also screened for ESBL production; no further isolates were identified.

The presence of a CTX-M-type, ESBL-producing isolate is rarely reported in the United States. The only other reference was from a multistate study in 2001–2002 that identified CTX-M type from \textit{E. coli} isolates from urine, sputum, and blood (6). No further reports about CTX-M–producing organisms have been disseminated. Our investigation suggests that CTX-M-type ESBLs may spread throughout the United States through infected travelers. This finding is notable because \textit{S. sonnei} is a common enteric pathogen. Our results further emphasize that travelers from others parts of the world can introduce highly mobile and clinically important resistance mechanisms into the community. The spread of CTX-M ESBLs may be faster and more widespread than previously thought; therefore, CTX-M type should be taken seriously as a surveillance target in the United States, especially in patients with a history of travel outside North America.

Seonghan Kim,* Jinxin Hu,* Romesh Gautam,* Junyoung Kim,† Bokkwon Lee,† and David S. Boyle*

*Washington Department of Health, Shoreline, Washington, USA; and †Korea Centers for Disease Control and Prevention, Seoul, Republic of Korea

References

1. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1–14.
2. White PA, Melver CJ, Deng Y, Rawlinson WD. Characterisation of two new gene cassettes, adaA5 and dfrA17. FEMS Microbiol Lett. 2000;182:265–9.
3. Kim S, Kim J, Kang Y, Park Y, Lee B. Occurrence of extended-spectrum beta-lactamases in members of the genus Shigella in the Republic of Korea. J Clin Microbiol. 2004;42:5264–9.
4. Conceicao T, Brizio A, Duarte A, Lito LM, Cristina JM, Salgado MG. First description of CTX-M–like producing Klebsiella pneumoniae in Portugal. Antimicrob Agents Chemother. 2005;49:477–8.
5. Eckert C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine A, et al. Dissemination of CTX-M–type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother. 2004;48:1249–55.
6. Moland ES, Black JA, Hossain A, Hanson ND, Thomson KS, Pottrumthy S. Discovery of CTX-M–like extended-spectrum beta-lactamases in Escherichia coli isolates from five US states. Antimicrob Agents Chemother. 2003;47:2382–3.

Address for correspondence: David S. Boyle, Washington Department of Health, Public Health Laboratories, 1610 NE 150th St, Shoreline, WA 98155-7224, USA; email: david.boyle@doh.wa.gov

HIV and Hepatitis C Virus Coinfection, Cameroon

To the Editor: Coinfection with HIV and hepatitis C virus (HCV) is now a major public health concern worldwide, owing both to its high prevalence (4–5 million persons of 40 million infected by HIV) and to interactions between the 2 diseases in terms of their diagnosis, natural course, and treatment (1,2). Although Africa is the continent by far the most badly affected by both HIV and HCV infections, data on coinfection in the general population are lacking. In Cameroon, a central African country, the HCV seroprevalence is among the highest in the world (13.8%) (3). We have also reported a high seroprevalence of HIV in a general population of southern Cameroon (7.4%), and especially in young women (22.5%) (4). Here, we investigated the prevalence of HIV/HCV coinfection in this population.

A population-based, cross-sectional survey was conducted in September 2001 in 3 villages of the East Province of Cameroon (250 km from Yaoundé, the capital city). The study methods, the baseline characteristics of the participants, and the HIV

Table. MICs of antimicrobial drugs for \textit{Shigella sonnei} clinical isolate WA7593 and its transconjugant WA7593TC1

| Antimicrobial drug          | WA7593 | WA7593TC1 |
|----------------------------|--------|-----------|
| Ampicillin                 | >256   | >256      |
| Cephalothin                | >256   | >256      |
| Cefotaxime                 | >32    | >32       |
| Ceftazidime                | 4      | 4         |
| Ceftiraxone                | >32    | >32       |
| Cefaclor                   | >256   | >256      |
| Imipenem                   | 0.19   | 0.25      |
| Trimethoprim/sulfamethoxazole | >32   | 0.032     |